Form D · Pharmaceuticals

Emmaus Life Sciences, Inc.

Torrance, CA · CIK 0000822370

Offering snapshot reported Jan 31, 2023 · SEC filing

Reported sold
$0
Offering amount: $235K
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 30, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 31, 2023Initial$0No comparison1SEC filing
Jan 20, 2023Initial$0No comparison3SEC filing
Jun 30, 2022Initial$110,000No comparison1SEC filing
Feb 16, 2021Initial$1,920,000No comparison10SEC filing
Oct 9, 2020Amendment$3,840,300$3,840,300vs Oct 7, 202018SEC filing
Oct 7, 2020Amendment$3,680,800$3,680,800vs Oct 7, 202018SEC filing
Oct 7, 2020Initial$0No comparison18SEC filing
Aug 7, 2020Initial$947,600No comparison18SEC filing
Jan 8, 2016Amendment$4,000,000$1,735,000vs Jul 2, 201515SEC filing
Jul 2, 2015Amendment$2,265,000$715,000vs Sep 30, 20149SEC filing
Sep 30, 2014Initial$1,550,000No comparison7SEC filing
Sep 30, 2014Initial$260,000No comparison6SEC filing
Jan 30, 2014Initial$415,000No comparison9SEC filing
Sep 17, 2013Initial$221,549No comparison5SEC filing
Jun 14, 2013Initial$72,500No comparison4SEC filing
Mar 12, 2013Initial$595,000No comparison16SEC filing
Dec 14, 2012Initial$135,846No comparison3SEC filing
Sep 7, 2012Initial$300,000No comparison4SEC filing
Nov 2, 2011Initial$270,000No comparison2SEC filing
Oct 26, 2011Initial$0No comparison19SEC filing
May 9, 2011Amendment$2,500,000$2,050,000vs Feb 17, 201112SEC filing
Feb 17, 2011Initial$450,000No comparison5SEC filing
Oct 18, 2010Initial$1,611,688No comparison4SEC filing
Aug 3, 2010Amendment$750,000$250,000vs Jun 18, 20103SEC filing
Jun 18, 2010Initial$500,000No comparison1SEC filing
Mar 18, 2010Initial$1,000,000No comparison1SEC filing
Mar 17, 2010Initial$200,000No comparison1SEC filing
Mar 17, 2010Initial$500,000No comparison2SEC filing
Sep 8, 2009Initial$2,043,000No comparison6SEC filing

Offering details

Securities
Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-472265
Represents the total exercise prices of warrants to purchase up to 500,000 shares of common stock at an exercise prices of $0.47 a share.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
noneNone

Source: Form D, filed Jan 31, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Len Brandt Director
Paul Buck Executive
George Carpenter Executive
Michael Darkoch Executive
Mark Desrosiers Executive
Maurice De Wald Director
Robert Dickey Director
Robert Follman Director
Henry T. Harbin Director
Geoffrey Harris Director
Daniel Hoffman Executive
David Jones Director
George Kallins Director
Willis Lee Director, Executive
Zachary Mc Adoo Director
Yasushi Nagasaki Executive
Yutaka Niihara Director, Executive
Masaharu Osato Director
John Pappajohn Director
Andrew Sassine Director
Walter Schindler Director
Lim Seah Director
George Sekulich Executive
Joseph Sherwood Executive
Robin Smith Director
Charles Stark Executive
Tommy Thompson Director
Thomas Tierney Director
Richard Turner Director
Jerome Vaccaro Director
Michal Votruba Director
Jane Pine Wood Director
Wei Peu Zen Director
Wei Peu (Derek) Zen Director
Ian Zwicker Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
21250 Hawthorne Blvd. Suite 800
Torrance, CA, 90503